Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 16, 2008. The report details a specific corporate action regarding share repurchases authorized by shareholders at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to a share buyback.
- Shares Purchased: 1,100,000 Ordinary shares.
- Purchase Price: 1,206.34 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 9.14% of total voting rights).
- Shares in Issue: 5,188,861,593 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding share capital through the cancellation of 1,100,000 shares purchased on December 16, 2008. This transaction increased the proportion of Treasury shares held by the Company to 9.14% of total voting rights.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,188,861,593) for calculating disclosure thresholds under FSA rules.
- Confirm the updated Treasury share count (474,194,158) and its impact on voting rights (9.14%).
- Note that this filing does not contain operational or financial performance data for the period.